Provides a unique source of information pertaining to the development of radiotracer generators and their use in troubleshooting and optimizing industrial processes. The publication describes the results of research undertaken on the characterization of 68Ge/68Ga, 137Cs/137mBa, 99Mo/99mTc and 113Sn/113mIn radiotracer generators.
This book provides detailed information on therapeutic radiopharmaceuticals and discusses emerging technologies which have potential for broad clinical implementation. Recent advances in molecular biology, radiopharmaceutical chemistry and radioisotope production have stimulated a new era for the use of radiopharmaceuticals for targeted radionuclide therapy (TRT). Emerging clinical trials include use of peptides and monoclonal antibodies radiolabeled with therapeutic radionuclides for cancer therapy. In addition, small molecules are used for the treatment of chronic diseases such as metastatic bone pain palliation and radiation synovectomy of inflammatory joints. In the interventional arena, therapy of primary and metastatic liver cancer and arterial restenosis following angioplasty of both the coronary and peripheral arteries are being explored. Reactor and accelerator production of therapeutic radioisotopes is also integrated into these discussions. The development and use of radiopharmaceutical targeting characteristics required for treatment of specific disease processes and how these are implemented for radiopharmaceutical design strategies are also described. Radiopharmaceuticals for Therapy will benefit audiences in nuclear medicine and radionuclide therapy and will thus prove an invaluable source of up-to-date information for students, radiopharmaceutical scientists and professionals working in the radiopharmacy and nuclear medicine specialties.
The idea of using tracers (chemical tracers, dyes, etc.) in the investigation of complex physical phenomena has always attracted the attention of scientists and engineers. When radioactive isotopes became available it was immediately recognized that they offered an almost ideal solution to tracer selection. Extensive experience has been gathered all over the world in the application of radioactive tracers in industry. This guide is devoted to reviewing the present status of the tracer method as such and to its applications to those branches of industry which have derived large benefits from the use of this technology.
The third edition of this classic in the field is completely updated and revised with approximately 30% new content so as to include the latest developments. The handbook and ready reference comprehensively covers nuclear and radiochemistry in a well-structured and readily accessible manner, dealing with the theory and fundamentals in the first half, followed by chapters devoted to such specific topics as nuclear energy and reactors, radiotracers, and radionuclides in the life sciences. The result is a valuable resource for both newcomers as well as established scientists in the field.
The third edition of this classic in the field is completely updated and revised with approximately 30% new content so as to include the latest developments. The handbook and ready reference comprehensively covers nuclear and radiochemistry in a well-structured and readily accessible manner, dealing with the theory and fundamentals in the first half, followed by chapters devoted to such specific topics as nuclear energy and reactors, radiotracers, and radionuclides in the life sciences. The result is a valuable resource for both newcomers as well as established scientists in the field.
Radionuclide therapy using bone targeting radiopharmaceuticals is an effective palliative care option to reduce pain associated with advanced disease with bone metastases. Over the last 20 years, suitable therapeutic radionuclides are more widely available, meaning that the benefits of pain palliation therapy could reach more patients. This publication provides a broad overview on the current status of radiopharmaceuticals for bone pain palliation. It covers production of radionuclides, identification of bone seeking carrier molecules, preparation of stable complexes, in vitro and in vivo evaluations and dosimetry studies which are part of the development of these radiopharmaceuticals for clinical use. Details on production and quality control of the currently available products, provided here will be of use to scientists involved in the development of these radiopharmaceuticals.
